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Intermolecular disulﬁde bondThe orthopoxvirus protein A33 forms a disulﬁde-bonded high molecular weight species that could be either a
homodimer or a heteromultimer. The protein is a major target for neutralizing antibodies and the majority of
antibodies raised against A33 only recognize the disulﬁde-bonded form. Here, we report that A33 is present as
a disulﬁde-bonded homodimer during infection. Additionally, we examined the function of intermolecular
disulﬁde bonding in A33 homodimerization during infection. We show that the cysteine at amino acid 62 is
required for intermolecular disulﬁde bonding, but not dimerization as this mutant was still able to form
homodimers. To investigate the role of disulﬁde-bonded homodimers during viral morphogenesis,
recombinant viruses that express an A33R with cysteine 62 mutated to serine were generated. The
recombinant viruses had growth characteristics similar to their parental viruses, indicating that
intermolecular disulﬁde-bonded homodimerization of A33 is not required for its function.and Immunology, University of
14642. Fax:+1 585 473 9573.
.M. Ward).
tment, University of Rochester,
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Vaccinia virus, which was used as a live-attenuated vaccine to
eradicate smallpox, belongs to the Poxviridae family. It has a large
double-stranded DNA genome of 200 kb, and the genome is predicted
to encode approximately 200 functional open reading frames (Moss,
2001). Unlike most DNA viruses, poxviruses replicate entirely in the
cytoplasm of infected cells in a specialized area known as the viral
factory. The ﬁrst form of infectious virions produced from the viral
factory is called intracellular mature virions (IMV). IMV represent the
majority of virions produced from an infected cell and remain within
the infected cell. A subset of IMV obtain an additional double
membrane envelope as the result of wrapping that occurs at the
trans-Golgi network (TGN) or early endosome to become intracellular
enveloped virions (IEV) (Hiller andWeber, 1985; Schmelz et al., 1994;
Tooze et al., 1993). IEV are transported from the site of wrapping to
the cell surface along microtubules and are released from the
cytoplasm by fusion of their outermost membrane with the plasma
membrane (Geada et al., 2001; Hollinshead et al., 2001; Rietdorf et al.,
2001; Ward and Moss, 2001a). Released virions retained on the cell
surface are called cell-associated enveloped virions (CEV). CEV are
required for the induction of actin tails and, hence, efﬁcient cell-to-cell
spread (Smith et al., 2002; Ward and Moss, 2001a). A subset of CEVare released from the cell surface and become extracellular enveloped
virions (EEV), which are responsible for long-range dissemination of
virus (Appleyard et al., 1971; Payne, 1980). Collectively, CEV and EEV
make up what are termed extracellular virions (EV).
Seven virus-encoded proteins, A33, A34, A36, A56, B5, F12, and
F13, have been shown to be speciﬁc for the enveloped forms, IEV, CEV,
and EEV, (Duncan and Smith, 1992; Engelstad et al., 1992; Isaacs et al.,
1992; Roper et al., 1996; van Eijl et al., 2002, 2000). Of these seven
proteins, A36 and F12 are exclusive to IEV (van Eijl et al., 2002, 2000;
Wolffe et al., 2001). A36 is involved in virion transport along
microtubules, while F12 is involved in virion egress (van Eijl et al.,
2002; Ward et al., 2003). The complex of A56 and K2 is known as
fusion regulatory proteins and associates with the entry/fusion
complex (Wagenaar and Moss, 2007). B5 and F13 have been shown
to be required for morphogenesis as deletion of either one of these
genes results in a decrease in enveloped virion production (Blasco and
Moss, 1991; Isaacs et al., 1992). Deletion of either A33 or A34
increases the amounts of EEV released into the media, and therefore,
they are believed to be involved in retention of CEV (Chan and Ward,
2010; McIntosh and Smith, 1996; Roper et al., 1998).
A33 is a type II integral membrane protein that forms disulﬁde-
bonded homodimers or heteromultimers (Roper et al., 1996). It
coordinates the incorporation of A36 into IEV membranes and,
subsequently, the production of actin tails (Wolffe, Weisberg, and
Moss, 2001). Deletion of A33R causes a small plaque phenotype. This
phenotype is due to a number of defects, including the inability to
form actin tails and a reduction in the infectiousness of EV (Chan and
Ward, 2010; Roper et al., 1998). A33 is a major target for antibody
neutralization of the enveloped form of the virus and is a potential
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(Hooper et al., 2003, 2004). Either passive transfer of A33 monoclonal
antibodies or vaccination with an A33R subunit vaccine, delivered as
either DNA or recombinant protein, confers protection against a lethal
poxvirus challenge in animal models (Fang et al., 2006; Fogg et al.,
2004; Hooper et al., 2000). A33 contains six cysteine residues: one in
the predicted cytoplasmic tail and ﬁve in the predicted extracellular
domain. We wanted to examine if intermolecular disulﬁde bonding of
A33 was required for its function during infection and, therefore,
mapped the cysteine(s) involved in intermolecular disulﬁde bonding.
While we were carrying out these experiments, a partial structure of
A33 was determined (Su et al., 2010). Although the partial structure
did not contain the cysteine at position 62 (C62), the authors
predicted that C62 was involved in intermolecular disulﬁde bonding
(Su et al., 2010). Here, we show that C62 is indeed required for
intermolecular disulﬁde-bonded homodimerization of A33 and that
A33 lacking the cysteine at amino acid 62 still forms homodimers. In
addition, we examined the function of intermolecular disulﬁde
bonding of A33 utilizing recombinant viruses that express A33R
containing cysteine-to-serine mutation at amino acid 62. Character-
ization of the recombinants revealed that disulﬁde-bonded homo-
dimerization of A33 is not required for the production of infectious
extracellular virions.
Results
Cysteine at amino acid position 62 is involved in intermolecular disulﬁde
bond formation
While A33 is predicted to encode a 21-kDa protein, it was shown to
migrate at 55 kDa under non-reducing conditions and a smear at 23–
28 kDa under reducing conditions, indicating that it forms either a
homodimer or a heteromultimer that is disulﬁde-bonded (Roper et al.,
1996). There are six cysteine residues in A33: one in the predictedA
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Fig. 1. Cysteine at amino acid 62 is involved in intermolecular disulﬁde bond formation. (A)
cytoplasmis tail (CT), transmembrane domain (TMD), and lumenal domain (LD) are shown.
cells were infected with vTF7.3 in the presence of AraC and transfected with the indicated pl
under either reducing or non-reducing conditions. The proteins were transferred to nitrocel
A33 MAb (10F10). The positions and molecular weights, in kilodalton, of marker proteins acytoplasmic tail andﬁve in the predicted lumenal domain (Fig. 1A).We
wanted to map the cysteine(s) involved in intermolecular disulﬁde
bond formation and, hence, homodimerization. Therefore, the six
cysteines in A33 were individually mutated to the structurally similar
amino acid, serine, and analyzed by Western blot under either
reducing or non-reducing conditions. As shown in Fig. 1B, the A33-
HAC62S mutant was detected as a band that is consistent with a
monomer under both reducing and non-reducing conditions. In
contrast, the other mutants, A33-HAC36S, A33-HAC100S, A33-HAC109S,
A33-HAC126S, and A33-HAC180S, along with A33-HA, were only
detected as monomers under reducing conditions and as forms
consistent with dimers and tetramers under non-reducing conditions
(Fig. 1B). Our results demonstrated that C62 is required for
intermolecular disulﬁde-bonded homodimerization. Several mono-
clonal antibodies raised against A33 are conformation-speciﬁc and are
only able to detect unreduced A33 (Chen et al., 2007; Golden and
Hooper, 2008). This raises the possibility that the epitope recognized
by those monoclonal antibodies spans the two subunits of an A33
homodimer. To test this possibility, we determined if the A33-HAC62S
mutant could be recognized by the conformation-speciﬁc antibody,
MAb-10F10 (Golden and Hooper, 2008). As expected, MAb-10F10
recognized forms consistent with dimers and tetramers in unreduced
lysates from cells expressing A33-HA and A33-HAC36S (Fig. 1B). It only
recognized themonomeric form of the A33-HAC62S, indicating that the
epitope is containedwithin a singlemonomer of A33. In contrast, it did
not recognize the unreduced forms of A33-HAC100S, A33-HAC109S, A33-
HAC126S, and A33-HAC180S.
Intermolecular disulﬁde bonding of A33 is not required for interaction
with B5-GFP
Interaction between A33 and B5, another enveloped-speciﬁc
protein encoded by the virus, has been reported (Perdiguero and
Blasco, 2006). We have found that A33 interacts with B5-GFP in the185
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111W.M. Chan et al. / Virology 408 (2010) 109–118absence of other viral late proteins and that A33 is required for B5-GFP
to be efﬁciently incorporated into enveloped virions, suggesting that
the interaction of A33 and B5-GFP may be necessary for B5-GFP
incorporation (Chan andWard, 2010) (Chan andWard, unpublished).
Therefore, we performed co-immunoprecipitation to determine if our
A33 cysteine-to-serine mutants were still capable of interacting with
B5-GFP. All of the A33 cysteine-to-serine mutants brought down a
band of the predicted size for B5-GFP (Fig. 2), indicating that all of
them are capable of interacting with B5-GFP. Furthermore, A33-HA,
A33-HAC36S, and A33-HAC62S immunoprecipitated similar amount of
B5-GFP. In contrast, A33-HAC100S, A33-HAC109S, A33-HAC126S, and
A33-HAC180S immunoprecipitated more B5-GFP compared to A33-HA
(Fig. 2). To rule out the possibility that the increased levels of B5-GFP
co-immunoprecipitated with these mutants was not due to differ-
ences in B5-GFP expression levels, cell lysates were analyzed by
Western blot using an anti-GFP antibody. As shown in Fig. 2,
equivalent levels of B5-GFP were expressed, indicating that the
greater amount of B5-GFP co-immunoprecipitated with these
mutants was not due to higher expression levels of B5-GFP. The
results were identical when B5 was used in place of B5-GFP (data not
shown).A33C62S still forms homodimers
A recombinant A33 expressed in bacterial cells that does not
contain amino acid residues 1 to 89 has been reported to exist as a
stable homodimer (Su et al., 2010). We, therefore, wanted toA
B
C
pB5R-GFP      +      +      +     +     +     +     +     +
pA
33
R-
HA
C3
6S
 
pA
33
R-
HA
C6
2S
pA
33
R-
HA
C1
00
S  
pA
33
R-
HA
C1
09
S 
pA
33
R-
HA
C1
26
S 
pA
33
R-
HA
C1
80
S 
pA
33
R-
HA
 
pc
DN
A3
A33-HA or
A33-HA mutants
B5-GFP
B5-GFP
ß-Actin
97
19
64
51
39
28
Fig. 2. A33-HAC62S interacts with B5-GFP. HeLa cells, infected with vTF7.3 in the
presence of AraC and transfected with the indicated plasmids, were incubated with
media containing [35 S]-Met/Cys at 4 h post-transfection. 24 h PI, cells were harvested
and lysed in RIPA buffer. Cell lysates were subjected to immunoprecipitation with an
anti-HA MAb. Antibody–protein complexes (A) or cell lysates (B and C) were resolved
by SDS–PAGE. Radiolabeled proteins were detected by autoradiography (A). The
positions andmolecular weights, in kilodalton, of marker proteins are shown. The levels
of B5-GFP (B) and ß-actin (C) in the cell lysates were detected byWestern blot using an
HRP-conjugated anti-GFP antibody or an anti-β-actin MAb, followed by an HRP-
conjugated donkey anti-mouse antibody, respectively.determine if full-length A33-HAC62S expressed in eukaryotic cells
could still from homodimers in the absence of intermolecular
disulﬁde bonding. To test this, we generated A33C62S with a V5-
epitope tag on its cytoplasmic tail (pV5-A33RC62S) and examined if
normal A33-HA or A33-HA cysteine-to-serine mutants could interact
with V5-A33C62S using co-immunoprecipitation. All of the A33-HA
cysteine-to-serine mutants, including A33-HAC62S, co-immunopreci-
pitated a band of the predicted size for V5-A33C62S (Fig. 3A),
indicating that the full-length A33-HAC62S can still dimerize when
expressed in eukaryotic cells. We also observed that A33-HAC100S,
A33-HAC109S, A33-HAC126S, or A33-HAC180S brought down more V5-
A33C62S than the unmutated A33-HA (Fig. 3A). To ensure that V5-
A33C62S was expressed at similar levels, cell lysates were analyzed by
Western blot using an anti-V5 antibody. As shown in Fig. 3C, the
greater amount of V5-A33C62S brought down with these mutants was
not due to a higher expression level of V5-A33C62S.
Generation of A33RC62S recombinant viruses
Our data indicate that A33C62S was still capable of forming
homodimers. We wanted to examine if A33C62S could replace A33
during infection even though it is incapable of forming disulﬁde-
bonded dimers. Therefore, we generated recombinant viruses
expressing A33RC62S that contains a serine at amino acid 62 in place
of normal A33R and either B5R-GFP (vB5R-GFP/A33RC62S) or normal
B5R (vA33RC62S). We generated recombinant viruses that express
A33RC62S in both vB5R-GFP and WR backgrounds because we have
previously shown that a recombinant virus that expresses B5R-GFP
and has A33R deleted produces smaller plaques than a recombinant
virus that only has A33R deleted, indicating that B5R-GFP is a more
sensitive indicator of defects in A33 (Chan and Ward, 2010).
Our initial analysis of A33C62S was conducted in the absence of late
viral protein synthesis. Wewanted to determine if A33C62S could form
disulﬁde-bonded homodimers during infection. Lysates of infected
cells were analyzed under reducing and non-reducing conditions by
Western blot using a polyclonal anti-A33 antibody. A33 has been
shown to migrate between 23 and 28 kDa on SDS–PAGE under
reducing conditions (Roper et al., 1996). As expected, A33C62S was
detected as a monomer under both reducing and non-reducing
conditions (Fig. 4). Normal A33 migrated at sizes consistent with
monomers, dimers, and tetramers under non-reducing conditions but
only as a monomer under reducing conditions (Fig. 4). To examine if
the conformation of A33C62S is retained in the presence of other viral
proteins, we performedWestern blots using MAb-10F10 under either
reducing or non-reducing conditions. Consistent with our previous
results, MAb-10F10 only recognized the monomeric form of A33C62S
and only under non-reducing conditions (Fig. 4).
A33C62S localizes properly in infected cells
We next examined the intracellular localization of A33C62S in
infected cells using immunoﬂuorescence microscopy. In cells infected
withWR or vB5R-GFP, A33 localized at the site of wrapping, at the cell
vertices, and on virion-sized particles in the cytoplasm (Fig. 5). In cells
infected with either vB5R-GFP/A33RC62S or vA33RC62S, the localiza-
tion pattern of A33C62S was identical to that seen in cells infected with
the parental viruses, WR and vB5R-GFP (Fig. 5). In addition, we also
examined the localization of B5 or B5-GFP in infected cells. In cells
infected with WR, vB5R-GFP, vB5R-GFP/A33RC62S, or vA33RC62S, B5-
GFP or B5 localization appeared normal with all three of the
characteristic hallmarks present, localization to the site of wrapping,
the cell vertices, and on virion-sized particles (Fig. 5) (Ward andMoss,
2001b). As had been shown before, all three characteristic hallmarks
of B5 localization were not observed in cells infected with either
vΔA33R or vB5R-GFP/ΔA33R (Fig. 5) (Chan and Ward, 2010). The
ability of A33C62S to restore proper localization of B5/B5-GFP in cells
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A33C62S appears to function normally during infection.
A33RC62S recombinant viruses form normal-sized plaques
Plaque size indicates the ability of orthopoxviruses to produce
infectious enveloped virions and their ability to spread from cell to
cell. To examine if infectious enveloped virions are produced by
A33RC62S recombinants, we compared the plaques made by our
recombinant viruses expressing A33RC62S to those made by the
parental viruses. Both vB5R-GFP/A33RC62S and vA33RC62S produced
plaques similar in size to those made by the parental viruses (Fig. 6),
indicating that intermolecular disulﬁde bonding of A33 is not required
for infectious enveloped virion production and actin tail formation.
Taken together, vB5R-GFP/A33RC62S and vA33RC62S had similar
subcellular localization (Fig. 5) and produced similar sized plaques
on cell monolayer (Fig. 6), indicating that they are identical.
Therefore, further characterization was only carried out on vA33RC62S.
The replication kinetics of vA33RC62S is similar to that of WR
Our previous result indicated that preventing the formation of
intermolecular disulﬁde-bonded A33 homodimers did not cause a
defect in infectious enveloped virion production (Fig. 6). To compare
the replication kinetics of vA33RC62S to that of WR, we determined the
amounts of infectious virions produced by WR or vA33RC62S using a
low MOI growth curve, which directly looks at the production of
infectious enveloped virions and their ability to spread from cell to
cell. We determined the amounts of infectious virions released into
the media and virions associated with the cells using plaque assays.
The titers of infectious virions released from the cells and associated
with the cells were identical between vA33RC62S and WR (Fig. 7),
showing that disruption of the intermolecular disulﬁde bonding
between A33 monomers does not have a noticeable effect on
infectious virion production.vA33RC62S and WR produce similar amounts of infectious EEV and CEV
Analysis of the growth property of vA33RC62S showed no
detectable defect. A33 has been shown to be required for optimal
production of fully infectious EEV and CEV (Chan and Ward, 2010).
We next examined the infectivity of EEV and CEV produced by
vA33RC62S and compared it to WR. The amounts of EEV and CEV
produced by cells infected with either WR or vA33RC62S were
determined using real-time PCR to quantify the genomes and plaque
assays to determine their infectivity. We found that vA33RC62S
produced similar amounts of EEV and CEV genome copies as well as
infectious EEV and CEV compared to WR (Fig. 8). Taken together, the
intermolecular disulﬁde bonding between A33 monomers appears
not to be required for its functions.
Discussion
A33 is one of seven enveloped virus-speciﬁc proteins encoded by
orthopoxviruses and is found in all of the members of the subfamily
Chordopoxvirinae, except for the members of the Avipoxvirus genus
(Roper et al., 1996). A33 was reported to be a disulﬁde-bonded
multimer in infected cells and has been reported to be palmitoylated
(Payne, 1992; Roper et al., 1998). The six cysteine residues in A33 are
highly conserved among the members of the subfamily Chordopox-
virinae. Of these six cysteine residues, C36 is predicted to be
palmitoylated as it is the only cysteine in the cytoplasmic tail
(Grosenbach et al., 2000; Payne, 1992). Of the remaining ﬁve
cysteines, C100, C109, C126, and C180 were recently reported to be
involved in intramolecular disulﬁde bond formation (Su et al., 2010).
Based on this ﬁnding, it was predicted that C62 would be involved in
intermolecular disulﬁde bonding of A33. Here, we show that C62 is
involved in linking two monomers covalently via a disulﬁde bond.
Interestingly, we found that disruption of the ability to form the
intermolecular disulﬁde bond did not prevent the formation of A33
homodimers. Subsequently, disruption of intermolecular disulﬁde
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during infection.
The fact that A33C62S still formed dimers establishes that there are
two mechanisms for homodimerization, one is through the intermo-
lecular disulﬁde bonding at C62 and the other, through interaction
between the speciﬁc residues in the dimer interface. There have been
two functions reported for A33 during viral infection. A33 has been
reported to coordinate the inclusion of viral proteins into the IEV
wrapping membrane (Wolffe et al., 2001). In addition, A33 contains a
C-type lectin-like domain that has been postulated to bind EV to the
cell surface (Su et al., 2010). It is unclear if A33 needs to be a dimer for
complete functionality during infection. The redundant mechanisms
for dimerization are indicative that it does. A recent report indicated
that the structure of the A33 homodimer contained dimers of the C-
type lectin-like domain, indicating that each monomer contains the
domain, and therefore, should be capable of binding ligand (Su et al.,
2010). It is unclear if A33 needs to be a dimer for it to coordinate
protein incorporation into the IEV membrane. It would be interesting
to identify the region of homodimerization in A33 in order to
determine if A33 can function as a monomer during infection.
A study has shown that vaccinationwith vaccinia virus elicits long-
lived antibody responses directed against virus-speciﬁc membrane
proteins in humans, one of which is A33 (Lawrence et al., 2007). In
addition, all of the vaccine recipients elicited anti-A33 antibodies aftervaccination, and therefore, A33 has been suggested for inclusion in a
potential subunit vaccines against orthopoxviruses (Lawrence et al.,
2007). The majority of monoclonal antibodies raised against A33 only
recognize unreduced A33, and therefore, the dimeric form (Chen et al.,
2007; Golden and Hooper, 2008; Roper et al., 1996). Surprisingly,
A33C62S is recognized as a monomer by a conformation-speciﬁc anti-
A33 monoclonal antibody under non-reducing conditions, indicating
that the antibody recognition epitope does not span the twomonomers
(Figs. 1 and 4). Conversely, A33-HAC100S, A33-HAC109S, A33-HAC126S, and
A33-HAC180S were not detected by the conformation-speciﬁc antibody
(Fig. 1B). These cysteineswere reported to be involved in intramolecular
disulﬁde bonding and are required for conformation, which is
apparently required for recognition by MAb-10F10 (Su et al., 2010).
Several studies have used a recombinant A33 protein for vaccination
studies to look at its ability to protect against a lethal orthopoxvirus
infection (Buchman et al., 2010; Fang et al., 2006; Fogg et al., 2004). The
A33 protein used in these studies still contained C62 and formed
disulﬁde-bonded homodimers. Our results suggest that a monomer of
A33 should be just as immunogenic.
A33 is detected as both a dimer and a tetramer under non-
reducing conditions (Fig. 4), raising the possibility that an additional
disulﬁde bond forms between two homodimers. Tetramer formation
appears to require intermolecular disulﬁde bonded homodimers
because mutating C62 abrogates A33 tetramer formation (Fig. 4).
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The next day, cells were ﬁxed, permeabilized, and stained with an anti-A33 MAb, followed by Texas Red-conjugated donkey anti-mouse antibody. B5 was visualized by either GFP
ﬂuorescence (vB5R-GFP, vB5R-GFP/A33RC62S, or vB5R-GFP/ΔA33R) or staining with an anti-B5 MAb, followed by FITC-conjugated donkey anti-rat antibody (WR, vA33RC62S,
vΔA33R). Cells were visualized using a ﬂuorescent microscope. Localization of B5-GFP or B5 (green) and A33 (red) at the site of wrapping (concave arrowheads), at the cell vertices
(arrows), and on virion-sized particles (arrowheads) are indicated. The DNA in nuclei and viral factories was stained with DAPI (blue). The overlap of green and red is shown as
yellow.
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virions asWR (Figs. 7 and 8), indicating that A33 tetramers appear not
to have an important role during infection.WR
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Fig. 7. vA33RC62S and WR produce similar amounts of infectious virions and spread at
similar rates. BS-C-1 cells were infected with either WR or vA33RC62S at a MOI of 0.01 in
duplicate. At the indicated times, supernatants were collected and cells were harvested
by scraping in fresh media. Virions released into the media (A) or associated with the
cells (B) were titered on fresh BS-C-1 cell monolayers. The averaged PFU/ml are shown.Our data show that A33C62S still interacts with B5-GFP and forms
homodimers (Figs. 2 and 3). It was interesting to ﬁnd that A33-
HAC100S, A33-HAC109S, A33-HAC126S, and A33-HAC180S co-immunopre-
cipitated a greater amount of B5 and B5-GFP than normal A33-HA
(Fig. 2). It is possible that disruption of intramolecular disulﬁde bond
formation causes the protein structure to be in a more relaxed state
and thus allows greater interaction with B5. In addition, A33-HAC100S,
A33-HAC109S, A33-HAC126S, and A33-HAC180S migrated as a doublet on
SDS–PAGE (Fig. 2). A33 has been shown to be glycosylated, and there
are two putative N-linked glycosylation sites (Payne, 1992). However,
it has not been shown if A33 is glycosylated at one or both sites.
Mutating the cysteines at positions 100, 109, 128, or 180 may have
exposed both of the glycosylation sites, and hence, the appearance of a
slower migrating band in addition to the band consistent with normal
A33-HA (Fig. 2). Mutants A33-HAC100S, A33-HAC109S, A33-HAC126S,
and A33-HAC180S interacted stronger with V5-A33C62S than normal
A33-HA, but not as well to themselves (Fig. 3), indicating that they
appeared to dimerize better with V5-A33C62S. It is unclear why these
mutants interact with A33C62S better than the normal A33.
Materials and methods
Construction of plasmids
Construction of pB5R-GFP has been described previously (Ward
and Moss, 2000). To construct pA33R-HA, the coding sequence of
A33R was ampliﬁed with a 5′ primer and a 3′ primer, which contains
the coding sequence of inﬂuenza hemagglutinin (HA) epitope tag,
using PCR. The resulting PCR fragment was inserted into pCR2.1
(Invitrogen) and subcloned into pcDNA3 (Invitrogen) that had been
digested with HindIII and XhoI restriction enzymes. To mutate
individual cysteines to serines, forward and reverse primers contain-
ing the desired mutation were generated. An overlapping two-step
PCR was performed using pA33R-HA as the template. The resulting
PCR fragments were inserted into pCR2.1 (Invitrogen) and subcloned
into pcDNA3 (Invitrogen) as described above to generate pA33R-
HAC36S, pA33R-HAC62S, pA33R-HAC100S, pA33R-HAC109S, and pA33R-
HAC126S. To construct pA33R-HAC180S, PCR was performed using
pA33R-HA as the template and a 5′ primer and a 3′ primer, which
contains the desired mutation and the coding sequence of an HA
epitope tag. To construct pA33R full, the coding sequence of A33R
containing 500-bp upstream and downstream regions were ampliﬁed
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Fig. 8. vA33RC62S and WR produce similar amounts of EEV and CEV. BS-C-1 cells were infected with either WR or vA33RC62S at a MOI of 10.0 in duplicate. 24 h PI, EEV containing
supernatants were collected and cell monolayers were incubated with media containing 1 μg per ml of trypsin at 37 °C for 1 h. Afterward, the media was collected (CEV). The
amounts of EEV and CEV producedwere measured by absolute quantiﬁcation of genome copies using real-time PCR (A) and their infectivity was determined by plaque assay on fresh
BS-C-1 cell monolayers (B). The averages of EEV or CEV and the error bars for each virus are plotted.
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constructed by digesting pV5-A33R fused to the coding sequence of
YFP encoding 1 to 158 amino acids with HindIII and BamHI. The
digested product was cloned to pcDNA3 (Invitrogen) that had been
digested with HindIII and BamHI. To construct pA33RC62S full or pV5-
A33RC62S, site-directed mutagenesis was performed using pfu Turbo
DNA polymerase (Stratagene) and pA33R full or pV5-A33R, respec-
tively, as the template. All constructs were veriﬁed by sequencing.
Construction of A33RC62S recombinants
Construction of vTF7.3, vB5R-GFP, WR, vB5R-GFP/ΔA33R, and
vΔA33R has been described (Chan and Ward, 2010; Earl and Moss,
1991; Roper et al., 1998; Ward and Moss, 2001b). To generate vB5R-
GFP/A33RC62S or vA33RC62S, cells infected with either vB5R-GFP/
ΔA33R or vΔA33R, respectively, were transfected with pA33RC62S full.
The next day, cells were harvested and cell lysates were plated on
fresh BS-C-1 cells. Plaques were picked, puriﬁed, and ampliﬁed as
described previously (Earl and Moss, 1991). The presence of the
desired mutation in the recombinants was veriﬁed by sequencing.
Immunoﬂuorescence microscopy
HeLa cells grown on coverslips were infected with vB5R-GFP, vB5R-
GFP/A33RC62S, vB5R-GFP/ΔA33R, WR, vA33RC62S, or vΔA33R at a
multiplicity of infection (MOI) of 1.0. The next day, ﬁxed and
permeabilized cellswere stainedwith an anti-A33MAb (10F10) (kindly
provided by Jay Hooper), followed by Texas Red-conjugated donkey
anti-mouse antibody (Jackson ImmunoResearch Laboratories). Cells
infected with either WR, vA33RC62S, or vΔA33R were stained with an
anti-B5 MAb, followed by FITC-conjugated donkey anti-rat antibody
(Jackson ImmunoResearch Laboratories). Coverslips were mounted as
previously described (Chan andWard, 2010). Cells were visualized andimaged as previously described (Ward, 2005). Images were processed
minimally and overlaid using Adobe Photoshop (Adobe).
Western blot analysis
HeLa cells were infected with vTF7.3 at a MOI of 5.0 and transfected
with pA33R-HA or pA33R-HA cysteine-to-serine mutants in the
presence of cytosine arabinoside (Sigma). The next day, cells were
harvested and lysed in radioimmunoprecipitation assay (RIPA) buffer.
Proteins were resolved on 4–12% Bis–Tris gels (Invitrogen) and
transferred to nitrocellulose membranes. A33-HA or A33-HA cysteine-
to-serine mutants were detected by Western blotting using a
Horseradish peroxidase (HRP)-conjugated anti-HA antibody (Roche)
or anti-A33MAb (10F10), followed by an HRP-conjugated donkey anti-
mouse antibody (Jackson ImmunoResearch Laboratories). To examine
the expression of A33 during normal infection, HeLa cells were infected
withWR, vA33RC62S, vΔA33R, vB5R-GFP, vB5R-GFP/A33RC62S, or vB5R-
GFP/ΔA33R at a MOI of 5.0. The next day, cells were processed as
described above. Western blot analysis was performed to detect A33 or
A33C62S using an anti-A33 rabbit antiserum (BEI Resources), or anti-A33
MAb (10F10), followed by an HRP-conjugated donkey anti-rabbit or
anti-mouse antibody, respectively (Jackson ImmunoResearch Labora-
tories). Bound antibodies were detected using chemiluminescent
reagents (Pierce) according to manufacturer's instructions. B5-GFP
was detected using an HRP-conjugated anti-GFP antibody. β-actin was
detected using an anti-β-actin MAb (Sigma), followed by an HRP-
conjugated donkey anti-mouse antibody (Jackson ImmunoResearch
Laboratories).
Co-immunoprecipitation
The procedure for immunoprecipitation has been described (Earley
et al., 2008). Brieﬂy, pA33R-HA or pA33R-HA cysteine-to-serine
117W.M. Chan et al. / Virology 408 (2010) 109–118mutants were co-transfected with either pB5R-GFP or pV5-A33RC62S
into HeLa cells infected with vTF7.3 in the presence of AraC. The next
day, cells were harvested and lysed as described above. To test the
interactionwith B5-GFP, transfectionmediawas removed 4 h after later
and replaced with media containing 50 μCi per milliliter of [35S]-Met/
Cys. Cell lysates were subjected to immunoprecipitation with an anti-
HAMAb(SantaCruzBiotechnology). Antibody–protein complexeswere
pulled down using Protein G Agarose (CalBiochem), resolved on 4–12%
Bis–Tris Gels (Invitrogen), and detected by autoradiography. To test
dimerization of A33-HA cysteine-to-serine mutants, Western blot
analysis was performed to detect V5-A33C62S using an HRP-conjugated
anti-V5 antibody (Invitrogen).Low MOI growth curves
The procedure for low MOI growth curves has been described
previously (Ward, 2005). Brieﬂy, BS-C-1 cells were infected with
either WR or vA33RC62S at a MOI of 0.01 in duplicate. At 6, 12, 18, 24,
48, 72, and 96 h PI, EEV containing media were collected and cells
were harvested by scraping in the media. Cells were frozen and
thawed three times to release the virions associatedwith the cells. The
amounts of infectious EEV and virions with the cells were determined
by plaque assays on fresh BS-C-1 cell monolayers.Quantiﬁcation of EEV and CEV
The procedure for quantiﬁcation of EEV and CEV has been
described previously (Chan and Ward, 2010). Brieﬂy, BS-C-1 cells
were infected with WR or vA33RC62S at a MOI of 10.0. 24 h PI, EEV
containing supernatants were collected. CEV were released by
treatment of cell monolayers with trypsin. Amounts of EEV and CEV
produced by the recombinants were determined by quantiﬁcation of
genome copies using real-time PCR. Infectious amounts of EEV and
CEV produced were determined by plaque assays on BS-C-1 cells.Acknowledgments
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